ALEMTUZUMAB IN THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHATIC LEUKEMIA
https://doi.org/10.51523/2708-6011.2011-8-2s-23
Abstract
The article elucidates the results of the international clinical research into the application of alemtuzumab in patients with chronic lymphatic leukemia (CLL) and presents the results of the application of alemtuzumab both in monotherapy and in the combination with chemomedicines (fludarabin, cyklofosfan). The received results testify that the application of alemtuzumab in CLL patients is an effective up-to-date method of therapy.
References
1. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath- 1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL) / J. Lundin // Blood. - 2002. - Vol. 100 (3). - P. 768-773.
2. Therapeutic role of alemtuzumab (Campath-1H) in patient, who have failed fludarabine: results of a large international study / M. J. Keating // Blood. - 2002. - Vol. 99. - P. 3554-3561.
3. Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival / P. Moreton [et al.] // J. Clin. Oncol. - 2005. - Vol. 23. - P. 2971-2979.
4. Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia / B. Kennedy [et al.] // Blood. - 2002. - Vol. 99. - P. 2245-2247.
Review
For citations:
Morozova O.M. ALEMTUZUMAB IN THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHATIC LEUKEMIA. Health and Ecology Issues. 2011;(2S):69-71. (In Russ.) https://doi.org/10.51523/2708-6011.2011-8-2s-23
Views: 229
Email this article 